SEC Form 4 filed by MAIA Biotechnology Inc.
$MAIA
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
SC 13D/A - MAIA Biotechnology, Inc. (0001878313) (Subject)
SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)
SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)
CEO to detail THIO-101 expansion trial and upcoming trials in multiple indications MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chief Executive Officer Vlad Vitoc, M.D. will present at the Biotech Showcase™ 2025 investor conference taking place in San Francisco, California January 13-15, 2025. Dr. Vitoc will also host one-on-one meetings with investors throughout the 3-day event. The live event will be followed by a virtual 2-day event on January 21-22, 2025. At the conference, Dr. Vitoc will discuss MAIA's recent clinical developments and targeted value-dr
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that two of the Company's independent directors, Ramiro Guerrero, JD, LL.M. and Stan V. Smith, Ph.D., purchased MAIA's common stock and warrants in each of the Company's recent private placement closings which occurred on November 1, 2024, and December 13, 2024. Total gross proceeds to MAIA from the closings were $3.4 million. Mr. Guerrero purchased a total of 141,952 shares and 141,952 warrants for an aggregate purchase price of approximately $300,000. Dr. Smith purchased a total of 125,000 shares and 125,000 warrants fo
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the FDA has designated THIO for the treatment of pediatric-type diffuse high-grade gliomas (PDHGG) as a drug for a "rare pediatric disease." "THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including pediatric high-grade glioma, which is among the most treatment-resistant cancers in children. THIO is shown to activate the immune system while evading tumor immunosuppression, a novel therapeutic approach for this devastating childhood disease," s
8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)
424B5 - MAIA Biotechnology, Inc. (0001878313) (Filer)
8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)
Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D. to its Scientific Advisory Board (SAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321173734/en/Professor Saadettin Kilickap, M.D., Scientific Advisor to MAIA Biotechnology (Photo: Business Wire) Dr. Kilickap is a professor at the Istinye University Faculty of Medicine, Department of Medical Oncology, Liv Hos
New Scientific Advisory Board member played instrumental role in FDA approval and commercialization of multiple blockbuster products CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB). With over 20 years of academic and biopharmaceutical industry experience, Dr. Vezan is a highly regarded leader in drug development of novel therapeutic modalities, including cell and gene therapies, and played a pivotal role in the devel
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)